Eloxx Pharmaceuticals, Inc. ELOX
We take great care to ensure that the data presented and summarized in this overview for Eloxx Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ELOX
Top Purchases
Top Sells
About ELOX
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Insider Transactions at ELOX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 16
2024
|
Sumit Aggarwal PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
165,000
+49.26%
|
-
|
|
Oct 16
2024
|
Steven D Rubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+50.0%
|
-
|
|
Oct 16
2024
|
Lindsay Androski Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+50.0%
|
-
|
|
Oct 16
2024
|
Alan Edmund Walts Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+48.11%
|
-
|
|
Dec 01
2021
|
Vijay Modur HEAD OF R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
64,373
-29.35%
|
$0
$0.72 P/Share
|
|
Dec 01
2021
|
Vijay Modur HEAD OF R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
219,326
+50.0%
|
-
|
|
Dec 01
2021
|
Sumit Aggarwal PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
81,933
-29.35%
|
$0
$0.72 P/Share
|
|
Dec 01
2021
|
Sumit Aggarwal PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
279,158
+50.0%
|
-
|
|
Dec 01
2021
|
Alan Edmund Walts Director |
BUY
Exercise of conversion of derivative security
|
Direct |
37,695
+50.0%
|
-
|
|
Nov 29
2021
|
Daniel E. Geffken INTERIM CFO |
BUY
Open market or private purchase
|
Direct |
50,000
+50.0%
|
$0
$0.72 P/Share
|
|
Jul 30
2021
|
Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC |
SELL
Payment of exercise price or tax liability
|
Direct |
459
-1.38%
|
$459
$1.32 P/Share
|
|
Jul 30
2021
|
Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC |
BUY
Exercise of conversion of derivative security
|
Direct |
1,563
+4.5%
|
-
|
|
May 25
2021
|
Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,835
-5.49%
|
$1,835
$1.39 P/Share
|
|
May 25
2021
|
Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+15.75%
|
-
|
|
May 13
2021
|
Tomer Kariv Director |
BUY
Open market or private purchase
|
Indirect |
5,925,925
+43.52%
|
$5,925,925
$1.35 P/Share
|
|
May 13
2021
|
Ran Nussbaum Director |
BUY
Open market or private purchase
|
Indirect |
5,925,925
+43.52%
|
$5,925,925
$1.35 P/Share
|
|
May 13
2021
|
Pontifax Management 4 G.P. (2015) Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
5,925,925
+43.52%
|
$5,925,925
$1.35 P/Share
|
|
May 13
2021
|
Rajesh B Parekh Director |
BUY
Open market or private purchase
|
Indirect |
2,466,666
+33.04%
|
$2,466,666
$1.35 P/Share
|
|
Apr 30
2021
|
Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC |
SELL
Payment of exercise price or tax liability
|
Direct |
459
-1.66%
|
$918
$2.18 P/Share
|
|
Apr 30
2021
|
Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC |
BUY
Exercise of conversion of derivative security
|
Direct |
1,562
+5.35%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 201K shares |
|---|